Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.
Actively Recruiting
Researchers are evaluating optimized pharmacologic treatments for patients with Takotsubo Syndrome, a condition often referred to as broken heart syndrome. This large randomized registry clinical trial aims to include 1000 participants registered in SWEDEHEART to better document effective treatments, as current data from large patient groups are lacking. The trial is a Phase 4 study sponsored by Vastra Gotaland Region and is designed as an open-label, multinational, multicenter trial. Participants are randomly assigned to different treatment groups. One group receives an adenosine infusion for 3 hours followed by oral dipyridamole twice daily until left ventricular function normalizes or up to about one month. Another group receives usual care per European Society of Cardiology recommendations. A separate randomization compares oral apixaban twice daily until normalization of heart function or about one month versus no anticoagulant therapy. The study monitors heart function with echocardiographic assessments at 48-96 hours and possibly later. During the study, participants undergo regular heart ultrasounds to assess wall motion and ejection fraction, along with monitoring for events such as death, cardiac arrest, heart failure, thromboembolic events, and bleeding. The trial collects data up to 30 days after treatment begins. Researchers also track heart rhythm problems and use standardized scoring to evaluate heart muscle movement. Safety and treatment outcomes are closely observed throughout the study period, which lasts until December 2028.
Actively Recruiting
Researchers are investigating the link between lung swelling lung edema and a protein called Heparin-binding Protein HBP in patients in intensive care units ICU. The study focuses on whether the levels of HBP in blood relate to lung blood vessel leakage and the amount of fluid in the lungs. It also looks at how HBP levels connect to the total fluid balance in the body. This observational study involves adult ICU patients monitored with a special device called PiCCO that measures lung fluid and blood flow. The study collects blood samples three times daily over up to three days while patients are monitored with the PiCCO system, which uses a technique called transpulmonary thermodilution to assess lung water and blood volumes. There are no additional treatments given as part of the study it only observes the natural course and measurements in these patients. The PiCCO device requires a central venous line and an arterial catheter and needs regular calibrations during the study period. Participants will have blood samples taken alongside the PiCCO calibrations, and data about lung water, blood volume, and fluid balance will be recorded. Researchers will analyze the relationship between HBP levels and pulmonary vascular permeability index PVPI, which indicates lung vessel leakage, as well as fluid balance. The study lasts while PiCCO monitoring continues, up to three days, with data kept confidential and handled according to privacy regulations. Any clinical findings from monitoring will be managed by the usual ICU care team without influence from the study.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating treatment options for older men aged 75 years or older with high-risk, non-metastatic prostate cancer. The study aims to compare immediate curative treatments like radiotherapy combined with hormone therapy or surgery to conservative approaches such as observation or hormone therapy. This trial addresses the uncertainty about whether immediate curative treatment offers survival benefits in older patients similar to those seen in younger men, while also considering quality of life and cost-effectiveness. Participants randomized to the immediate curative therapy group will receive either radiotherapy plus hormone therapy or surgery based on patient preference, with radiotherapy plus hormone therapy being the standard. Those assigned to the conservative group will be observed or receive hormone therapy depending on disease status, with further treatment given based on disease progression. This phase 3 randomized trial compares these two approaches over an extended period. Throughout the study, participants will be regularly evaluated for overall survival and disease burden up to 10 years after recruitment ends. Secondary assessments include monitoring urinary, bowel, and prostate cancer-related symptoms, quality of life, functional status, and the need for additional therapies. The study involves ongoing monitoring to understand long-term outcomes and side effects, supporting comprehensive assessment of treatment impact for this older population.
Actively Recruiting
This observational study focuses on women aged 18 and older diagnosed with urgency or mixed urinary incontinence who have received a medical evaluation and first-line treatment recommendation. It evaluates the use and effectiveness of the Te4taeII app following contact with ordinary healthcare. Researchers aim to determine whether treatment via this app is effective and feasible after primary care. Participants will use the Te4taeII app for 15 weeks to manage their urinary incontinence. The app provides education on pelvic floor and urinary incontinence, bladder training, pelvic floor muscle exercises, and psychoeducation. It includes features like reminders, exercise visualization, and feedback on symptom changes. Access to the app requires a one-time activation code provided after study inclusion. Women will complete online questionnaires before starting treatment, after 15 weeks, and one year later to assess symptoms, quality of life, and improvement. These include validated tools like the ICIQ-UI SF and ICIQ-LUTSqol. The study collects data on app usability, satisfaction, and desire for further treatment. Follow-up is conducted digitally, and the primary outcome is the symptom score change from start to 15 weeks.
Actively Recruiting
Spontaneous intracerebral hemorrhage ICH is a serious type of stroke with high death and disability rates. Researchers are investigating whether a structured treatment package called a Care Bundle can improve the 3-month outcomes for patients with acute ICH compared to standard care. The study is an international, multicenter, parallel, cluster-randomized clinical trial focusing on implementing this Care Bundle in high-income countries, building on results from previous trials mostly done in low- and middle-income countries. The Care Bundle includes early intensive blood pressure lowering, treatment of fever and high blood sugar, rapid reversal of oral anticoagulation, and timely referrals to intensive care or neurosurgery when needed. Hospitals are randomized in batches through three phases usual care, randomized evaluation of the Care Bundle versus usual care, and a post-implementation follow-up where all hospitals apply the Care Bundle. Each batch lasts 18 months, with 6 months per phase, and the overall study rollout spans 2.5 years. Participants are adults aged 18 or older diagnosed with spontaneous ICH confirmed by imaging within 24 hours of symptom onset. During the study, patient management details and outcomes will be closely monitored, including brain imaging, blood pressure, glucose levels, and functional status. The primary outcome is functional recovery measured by a utility-weighted modified Rankin Scale score at 180 days. Secondary outcomes include disability, death, and health-related quality of life. The study also collects data on treatments and care decisions to evaluate the Care Bundles effectiveness and sustainability.
Actively Recruiting
Researchers are evaluating a new e-health program designed to improve the neurodevelopment of very preterm infants, born before 32 weeks or with low birth weight, by supporting parents in responsive caregiving. The study aims to see if this program, called INSPIRE, can enhance cognitive, motor, feeding, language, and socio-emotional development up to 2 years of age. Additional goals include assessing parental stress, emotional availability, health inequalities, and gender differences. This trial is conducted by Ume University with a multi-professional team and builds on a pilot study involving nine families. The intervention group will receive the INSPIRE program, which consists of 18 sessions delivered digitally over two years, starting at hospital discharge. This program focuses on strengthening parent-child interactions and empowering parents with responsive parenting skills. Families in the control group will receive standard care without the INSPIRE intervention. The study randomly assigns families to either group and follows up with assessments over time. Participants will be involved from discharge through at least 2 years corrected age, with evaluations including neurodevelopmental tests such as the Bayley Scales of Infant Development at 24 months. Additional assessments cover motor skills, language, feeding, emotional availability, parental stress, and mental health using various standardized tools at multiple time points up to 5.5 years of age. Researchers will monitor child development, parent well-being, and other outcomes to understand the interventions impact and safety over the study period.
Actively Recruiting
Researchers are studying complications after closing a temporary loop ileostomy in patients who had surgery for rectal cancer. The study aims to answer two main questions whether the choice of anastomotic method affects recovery after surgery, and if using a mesh to close the stoma site can reduce hernias. This is a prospective randomized trial involving multiple centers to explore these surgical techniques. Participants are randomly assigned to receive either a stapled anastomosis using a linear staple device or a hand-sewn anastomosis with a running monofilament suture. Additionally, there is an optional randomization to close the stoma site either with a lightweight mesh placed under the muscle or with a long-lasting suture. The skin and fascia are closed with running monofilament sutures, including a pursestring technique for the skin. During the study, researchers will monitor participants for postoperative bowel obstruction within 30 days and for stoma site hernias over 2 years. They will also assess other complications and hospital stay length within 30 days. Participants will undergo follow-up visits to evaluate these outcomes and ensure proper recovery. The total participation timeline includes short-term and long-term monitoring to capture relevant surgical results.
Actively Recruiting
Researchers are evaluating the effects of a restrictive strategy for giving non-resuscitation fluids to adult patients with septic shock. This trial aims to compare a protocolized reduction of these fluids against usual care to assess both beneficial and harmful impacts on patients during intensive care. The study focuses on adults who meet specific septic shock criteria, including infection suspicion, elevated plasma lactate, and need for vasopressors. Participants are randomly assigned to one of two groups. In the experimental group, non-resuscitation fluids are given according to a strict protocol that starts within two hours of randomization and continues during the ICU stay, up to 90 days. This protocol includes guidelines about maintenance fluids, intravenous and enteral hydration, nutrition, glucose use, and medication concentration. The other group receives fluids according to local standard practices with some general guidelines. Both groups are monitored throughout their ICU admission. During the study, participants undergo regular assessments including survival status at 90 days, complications in the ICU, and number of days free from mechanical ventilation within 90 days. Researchers also evaluate cognitive function and health-related quality of life six months after inclusion. The trial uses triple masking and follows participants from enrollment through ICU discharge and beyond, with the total participation lasting up to several months depending on individual outcomes.
1-10 of 15
1